دور البروموكريبتين في إحداث الإباضة لدى مريضات فرط برولاكتين الدم
Abstract
أجريت الدراسة في قسم التوليد وأمراض النساء - مشفى الأسد الجامعي – اللاذقية – سوريا, وامتدت من تاريخ 1/1/2003 وحتى 31/6/2004 وضمت 65 مريضة بين عمر 18 – 40 سنة وكانت نتائج الدراسة على النحو التالي :
عدد مريضات فرط برولاكتين الدم ضمن الفئة العمرية من 26-35 سنة 39 مريضة (60%).
عدد مريضات فرط برولاكتين الدم عند السيدات اللواتي حملن من قبل 44 مريضة (67.69%).
عدد مريضات ثر الحليب 53 مريضة, كان برولاكتين الدم مرتفعاً لدى 26 مريضة منهن (49,06%).
عدد مريضات فرط برولاكتين الدم 38 مريضة, عانت 26 مريضة من ثر الحليب (68,24%).
استخدم الإيكو المهبلي ومخطط الحرارة الأساسي في تحري الإباضة.
عدد المريضات اللواتي شخص لديهن إباضة ولم يحتجن إلى المعالجة بالبروموكريبتين 27 مريضة (41.54%).
عدد المريضات اللواتي لم يكن لديهن إباضة واحتجن للمعالجة بالبروموكريبتين 38 مريضة(48,46%).
تم تطبيق العلاج بالبروموكريبتين [2.5-7.5 ملغ / يوم على ثلاث جرعات] لدى 38 مريضة ولمدة 3 دورات حسب حاجة المريضة مع مراقبة حدوث الإباضة لديهن شهرياً.
حدثت الإباضة لدى 30 مريضة (78.95%). وفشلت لدى 8 مريضات (21.05%).
عدد الدورات العلاجية بالبروموكريبتين 77 دورة.
الآثار الجانبية المشاهدة للبروموكريبتين هي : هبوط ضغط انتصابي 8 مريضات (21.05%) ,غثيان 7 مريضات (18.42%)، إقياء 5 مريضات (13.16%)، صداع 4 مريضات (10.53%)، ألم معدي 6 مريضات (15.59%) .
The study was carried out in the Department of Obstetrics and Gynecology at Alassad University Hospital in Lattakia from 1/1/2003 to 31/6/2004.
The study included 65 patients between 18 – 40 years and the results were :
Number of hyperprolactinemia patients within the age from 26 – 35 years is 39 patients (60%).
Number of hyperprolactinemia in ladies who had pregnancy previously is 44 patients (67.69%).
Number of galactorrhea patients is 53 ,out of which blood prolactin was high in 26 patients (49,06%) .
Number of hyperprolactinemia patients is 38 , out of which 26 patients suffered from galactorrhea (68,24%).
We used vaginal ultrasound and basal body temprature in ovulation detection .
The number of patients who had ovulation without needing therapy by bromocriptin was 27 (41.54%).
The number of patients who did not have ovulation and who needed therapy by bromocriptin was 38 (58.46%) .
Therapy by bromocriptin was applied ( 2.5 -7.5 mg daily three doses ) in 38 patients for three cycles as The patient needed with monitoring ovulation monthly.
30 patients had ovulation (78.95%), and 8 patients failed (21.05%).
The number of therapeutic cycles by bromocriptin was 77 cycles.
Side effects of bromocriptin were : orthostatic hypotension 8 patients (12.05%), nausae 7 patients (18.42%), vomiting 5 patients (13.16%), headache 4 patients (10.53%), gastric
pain 6 patients (15.59%).
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.